Aquestive Presents Pharmacokinetic Data for Anaphylm, an Investigational Epinephrine Film, at ACAAI 2026

Key Takeaways

• Aquestive Therapeutics presented two oral and two poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) 2026 Annual Meeting in Phoenix, on its investigational epinephrine film, Anaphylm (dibutepinephrine).
• Three of the four covered the drug’s pharmacokinetics and pharmacodynamics, including in people with and without symptoms of an allergic reaction and with placement on top of the tongue. The fourth examined healthcare provider views on unmet needs in epinephrine delivery.
• Anaphylm is not approved. The company’s announcement describes the topics but doesn’t report any results, and the data are early-stage pharmacology rather than evidence of clinical benefit.

Aquestive Therapeutics, based in Warren, New Jersey, announced that multiple oral and poster presentations would be featured at ACAAI 2026, which ran November 12 to 16. Anaphylm is a polymer-based epinephrine prodrug in a sublingual film about the size of a postage stamp that dissolves on contact, without water or swallowing. The company says the packaging is thinner and smaller than a credit card and is designed to withstand rain and sunlight. If the FDA approves it, the company says, Anaphylm would be the first oral rescue medication for severe allergic reactions, including anaphylaxis. The FDA has conditionally approved the proposed trade name, contingent on approval of the product.

Two oral presentations were given on Saturday, November 14, in the Distinguished Industry and Late-breaking Oral Abstracts session. Jay A. Lieberman, M.D., presented “Dibutepinephrine Pharmacokinetics/Pharmacodynamics in Patients With and Without Symptoms of a Type I Allergic Reaction.” Matthew Greenhawt, M.D., MBA, MSc, presented “Pharmacokinetics and Pharmacodynamics of Top-of-Tongue Placement of Dibutepinephrine Sublingual Film.”

Two posters were presented on Friday, November 13. David B.K. Golden, M.D., presented a poster on the pharmacodynamic effects of the film, referred to as AQST-109, at low systemic epinephrine exposures. Karen Rance, DNP, CPNP, was lead author of a poster on healthcare provider perspectives on unmet needs and clinical considerations for epinephrine delivery in anaphylaxis. The abstracts were posted online by ACAAI on November 12.